Değer202020212022202320242025TTMSatış/genel/idari giderler5.32 M7.25 M6.48 M6.07 M7.44 M4.29 M—Araştırma ve geliştirme17.29 M21.13 M20.79 M20.78 M16.65 M7.99 M—Faaliyet karı24.81 M30.95 M26.94 M26.51 M22.21 M14.03 M—Faaliyet Dışı Gelir, Toplam———————Faiz gideri (aktifleştirilmiş faizler düşüldükten sonra)———————Faaliyet Dışı Gelir (Faiz Giderleri Hariç)———————Olağandışı gelirler/giderler———————Vergi öncesi kar26.17 M30.43 M29.75 M25.99 M18.05 M13.5 M—Kazançlardaki özsermayeler———————Vergiler32 K13 K90 K33 K9 0001 000—Kontrol gücü olmayan/azınlık payı2.83 M2.65 M3.21 M2.08 M1.57 M658 K—Vergi sonrası diğer gelirler/giderler———————Durdurulan faaliyetler öncesi net kar26.21 M30.45 M29.84 M25.95 M18.05 M2.15 M—Durdurulan faaliyetler—————5.67 M—Net kar26.21 M30.45 M29.84 M25.95 M18.05 M7.83 M—Seyreltme ayarlaması———————İmtiyazlı temettüler———————Adi hisse senedi sahiplerine düşen seyreltilmiş net kar———————Temel hisse başına kazanç (Temel EPS)———————Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)———————Dolaşımdaki ortalama adi hisse senedi sayısı———————Dolaşımdaki seyreltilmiş hisse senedi sayısı———————FAVÖK-24.24 M————-9.42 M—FVÖK-24.24 M-30.19 M-26.03 M-24.82 M-19.53 M-9.94 M—Gelir maliyeti574 K767 K909 K1.69 M2.68 M4.09 M—Satılan malların diğer maliyeti———————Amortisman ve itfa (nakit akışı)0————522 K—
Evogene Ltd. - Ordinary Shares
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture.